Scarica l'app Stockscreener
15.03
18.16%
2.31
Gh Research Plc Borsa (GHRS) Ultime notizie
GH Research announces annual general meeting for July 31 - Investing.com
GH Research Announces AGM and Key Resolutions for July 2025 - TipRanks
J Sainsbury plc (OTCMKTS:JSAIY) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Millennium Management LLC Acquires Shares of 20,761 GH Research PLC (NASDAQ:GHRS) - Defense World
GH Research to Participate in Neuro Perspectives Conference - TipRanks
Two Sigma Investments LP Makes New Investment in GH Research PLC (NASDAQ:GHRS) - Defense World
Cantor Fitzgerald Weighs in on GH Research FY2026 Earnings - Defense World
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) With Overweight Rating - Insider Monkey
GH Research (NASDAQ:GHRS) Now Covered by Cantor Fitzgerald - Defense World
GHRS Stock Coverage Initiated with Positive Outlook | GHRS Stock News - GuruFocus
cantor fitzgerald maintains overweight rating on gh research stock By Investing.com - Investing.com Canada
cantor fitzgerald maintains overweight rating on gh research stock - Investing.com Australia
BNP Paribas Financial Markets Takes $44,000 Position in GH Research PLC (NASDAQ:GHRS) - Defense World
How To Trade (GHRS) - news.stocktradersdaily.com
Northern Trust Corp Has $286,000 Holdings in GH Research PLC (NASDAQ:GHRS) - Defense World
GH Research to Present at ASCP Meeting on Breakthrough Depression Treatment - TipRanks
(GHRS) Long Term Investment Analysis - news.stocktradersdaily.com
GH Research to Present at ASCP Meeting on Depression Treatments - TipRanks
GH Research PLC (NASDAQ:GHRS) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Beckley’s psychedelic reduces depression - BioWorld MedTech
GH Research (NASDAQ:GHRS) Upgraded at Cantor Fitzgerald - Defense World
GH Research (GHRS) Highlights Phase 2b Results at Clinical Confe - GuruFocus
GH Research (GHRS) Highlights Phase 2b Results at Clinical Conference | GHRS Stock News - GuruFocus
GH Research Showcases Promising Depression Treatment Data at ASCP Meeting - TipRanks
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting - Yahoo
GH Research’s (GHRS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Guggenheim Cuts GH Research (NASDAQ:GHRS) Price Target to $29.00 - Defense World
GH Research (GHRS) Price Target Lowered by Guggenheim | GHRS Sto - GuruFocus
GHRS Stock: HC Wainwright & Co. Reiterates Buy Rating | GHRS Sto - GuruFocus
GH Research: Promising Clinical Results and Strong Financial Position Justify Buy Rating - TipRanks
GH Research (GHRS) Price Target Lowered by Guggenheim | GHRS Stock News - GuruFocus
Psychedelic: Compass, GH Research, MindMed report quarterly earnings - Yahoo Finance
GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
GHRS Reports Strong Financial Position with Increased Cash Holdi - GuruFocus
GH Research Reports Q1 2025 Financial Results Amidst Ongoing Challenges - TipRanks
GH Research PLC Reports Positive Phase 2b Trial Results for GH001 in Treatment-Resistant Depression and Financial Update for Q1 2025 - Nasdaq
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
What Makes GH Research (GHRS) a New Buy Stock - Yahoo Finance
Where are the Opportunities in (GHRS) - news.stocktradersdaily.com
Hims & Hers Health (NYSE:HIMS) Shares Down 8.3% Following Insider Selling - American Banking and Market News
Legal & General Group Plc Sells 18,302 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World
What Will GH Research PLC (NASDAQ: GHRS) Be Like In 2025 - Stocksregister
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
(GHRS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
(GHRS) Proactive Strategies - news.stocktradersdaily.com
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Guggenheim starts GH Research at Buy, sees long-term upside potential - Yahoo Finance
Guggenheim Initiates Coverage of GH Research (GHRS) with Buy Recommendation - Nasdaq
GH Research PLC (GHRS) Shares Rise Despite Market Challenges - The News Heater
How to Take Advantage of moves in (GHRS) - news.stocktradersdaily.com
GH Research (NASDAQ:GHRS) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
GH Research PLC (NASDAQ:GHRS) Receives $30.67 Consensus PT from Brokerages - Defense World
Q1 Earnings Forecast for GH Research Issued By HC Wainwright - Defense World
RBC Capital Initiates Coverage of GH Research (GHRS) with Outperform Recommendation - Nasdaq
FY2029 EPS Estimates for GH Research Lifted by HC Wainwright - Defense World
GH Research initiated with an Outperform at RBC Capital - TipRanks
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):